Literature DB >> 22696324

Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.

Cindy Farquhar1, Julie Brown, Jane Marjoribanks.   

Abstract

BACKGROUND: Surgical ovarian wedge resection was the first established treatment for women with anovulatory polycystic ovary syndrome (PCOS) but was largely abandoned both due to the risk of postsurgical adhesions and the introduction of medical ovulation induction. However, women with PCOS who are treated with medical ovulation induction, with drugs such as gonadotrophins, often have an over-production of follicles which may result in ovarian hyperstimulation syndrome and multiple pregnancies. Moreover, gonadotrophins, though effective, are costly and time-consuming and their use requires intensive monitoring. Surgical therapy with laparoscopic ovarian 'drilling' (LOD) may avoid or reduce the need for medical ovulation induction, or may facilitate its usefulness. The procedure can be done on an outpatient basis with less trauma and fewer postoperative adhesions than with traditional surgical approaches. Many uncontrolled observational studies have claimed that ovarian drilling is followed, at least temporarily, by a high rate of spontaneous ovulation and conception, or that subsequent medical ovulation induction becomes easier.
OBJECTIVES: To determine the effectiveness and safety of laparoscopic ovarian drilling compared with ovulation induction for subfertile women with clomiphene-resistant PCOS. SEARCH
METHODS: We used the search strategy of the Menstrual Disorders and Subfertility Group (MDSG) to search the MDSG Trials Register, CENTRAL, MEDLINE, EMBASE, CINAHL and PsycINFO. The keywords included polycystic ovary syndrome, laparoscopic ovarian drilling, electrocautery and diathermy. Searches were conducted in September 2011, and a further search of the MDSG Trials Register was made on 14 May 2012. SELECTION CRITERIA: We included randomised controlled trials of subfertile women with clomiphene-resistant PCOS who undertook laparoscopic ovarian drilling in order to induce ovulation. DATA COLLECTION AND ANALYSIS: This is an update of a previously updated review. There were nine RCTs in the previous version; an additional 16 trials were added in the current (2012) update. All trials were assessed for quality. The primary outcomes were live birth and multiple pregnancy. The secondary outcomes were rate of miscarriage, ovulation and pregnancy rates, ovarian hyperstimulation syndrome (OHSS), quality of life and cost. MAIN
RESULTS: Nine trials, including 1210 women, reported on the primary outcome of live birth rate per couple. Live births were reported in 34% of women in the LOD groups and 38% in other medical treatment groups. There were five different comparisons with LOD and there was no evidence of a difference in live births when compared with clomiphene citrate + tamoxifen (OR 0.81; 95% CI 0.42 to 1.53; P = 0.51, 1 trial, n = 150), gonadotrophins (OR 0.97; 95% CI 0.59 to 1.59; P = 0.89, I(2) = 0%, 2 trials, n = 318), aromatase inhibitors (OR 0.84; 95% CI 0.54 to 1.31; P = 0.44, I(2) = 0%, 2 trials, n = 407) or clomiphene citrate (OR 1.21; 95%CI 0.64 to 2.32; 1 trial, n=176, P= 0.05). There was evidence of significantly fewer live births following LOD compared with clomiphene citrate + metformin (OR 0.44; 95% CI 0.24 to 0.82; P = 0.01, I(2) = 78%, 2 trials, n = 159); the high heterogeneity in this subgroup could not be explained by population differences or differences in quality of the trials.Thirteen trials reported on multiple pregnancies (n= 1305 women). There were no cases of multiple pregnancies in either group for clomiphene citrate or aromatase inhibitors compared with LOD. The rate of multiple pregnancies was significantly lower in the LOD group compared with trials using gonadotrophins (OR 0.13; 95% CI 0.03 to 0.52; P=0.004, I(2) = 0%, 5 trials, n = 166). AUTHORS'
CONCLUSIONS: There was no evidence of a significant difference in rates of clinical pregnancy, live birth or miscarriage in women with clomiphene-resistant PCOS undergoing LOD compared to other medical treatments. The reduction in multiple pregnancy rates in women undergoing LOD makes this option attractive. However, there are ongoing concerns about the long-term effects of LOD on ovarian function.

Entities:  

Mesh:

Year:  2012        PMID: 22696324     DOI: 10.1002/14651858.CD001122.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  50 in total

1.  Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches.

Authors:  Uche Anadu Ndefo; Angie Eaton; Monica Robinson Green
Journal:  P T       Date:  2013-06

Review 2.  Ultrasound-guided transvaginal ovarian needle drilling for clomiphene-resistant polycystic ovarian syndrome in subfertile women.

Authors:  Jing Zhang; Liulin Tang; Linglingli Kong; Taixiang Wu; Liangzhi Xu; Xin Pan; Guan J Liu
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

3.  How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology.

Authors:  P Moghetti; E Carmina; V De Leo; A Lanzone; F Orio; R Pasquali; V Toscano
Journal:  J Endocrinol Invest       Date:  2015-04-03       Impact factor: 4.256

Review 4.  Ovulation Induction for the General Gynecologist.

Authors:  Steven R Lindheim; Tanya L Glenn; Megan C Smith; Pascal Gagneux
Journal:  J Obstet Gynaecol India       Date:  2018-05-12

Review 5.  Chinese herbal medicine for subfertile women with polycystic ovarian syndrome.

Authors:  Kunyan Zhou; Jing Zhang; Liangzhi Xu; Taixiang Wu; Chi Eung Danforn Lim
Journal:  Cochrane Database Syst Rev       Date:  2016-10-12

6.  Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.

Authors:  Lisa M Shandley; Amy Fothergill; Jessica B Spencer; Ann C Mertens; Hanh N Cottrell; Penelope P Howards
Journal:  Fertil Steril       Date:  2018-02-07       Impact factor: 7.329

Review 7.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

8.  Actin polymerization-enhancing drugs promote ovarian follicle growth mediated by the Hippo signaling effector YAP.

Authors:  Yuan Cheng; Yi Feng; Lina Jansson; Yorino Sato; Masashi Deguchi; Kazuhiro Kawamura; Aaron J Hsueh
Journal:  FASEB J       Date:  2015-02-17       Impact factor: 5.191

9.  Unilateral Versus Bilateral Laparoscopic Ovarian Drilling Using Thermal Dose Adjusted According to Ovarian Volume in CC-Resistant PCOS, A Randomized Study.

Authors:  Mohamed Lotfy Mohamed El-Sayed; Mostafa Abdo Ahmed; Marwa Abdel Azim Mansour; Shymma Abdel Azim Mansour
Journal:  J Obstet Gynaecol India       Date:  2017-06-02

10.  Hormonal Changes After Laparoscopic Ovarian Diathermy in Patients with Polycystic Ovarian Syndrome.

Authors:  Elsayed A Elnaggar; Youssef Abo Elwan; Safaa A Ibrahim; Mena M Abdalla
Journal:  J Obstet Gynaecol India       Date:  2016-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.